Ceapro Inc. Announces Publication of Results for a New PGX Processed Chemical Complex in the Journal of Supercritical Fluids
December 17, 2019 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports 2019 Third Quarter Financial Results and Operational Highlights
November 13, 2019 09:00 ET
|
Ceapro Inc.
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Maintained R&D focus on the development of delivery systems - - Third...
Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides
October 29, 2019 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Begins Trading on the OTCQX Best Market
October 16, 2019 07:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro to Present PGX Technology at the 3rd International Symposium on Pharmaceutical Engineering Research
September 25, 2019 08:30 ET
|
Ceapro Inc.
EDMONTON, Alberta, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Inc. to Present at the Fall Investor Summit in New York
September 10, 2019 08:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Inc. Reports 2019 Second Quarter and Six-Month Financial Results and Operational Highlights
August 28, 2019 09:00 ET
|
Ceapro Inc.
- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company - - Increased R&D investment focused on the development of delivery systems - ...
Ceapro Announces Research Funding Award from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada for Joint Projects with McMaster University
August 27, 2019 08:45 ET
|
Ceapro Inc.
- Collaboration to develop innovative drug delivery systems using disruptive PGX Technology to optimize drug formulations used in areas of high unmet medical needs such as idiopathic lung fibrosis and...
Ceapro Inc. Announces Signing of a Contribution Agreement with National Research Council of Canada
August 15, 2019 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...
Ceapro Announces Results of 2019 Shareholders’ Meeting
June 10, 2019 16:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, June 10, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of...